Niclosamide

Niclosamide

SCHEMBL23753582

NS(=O)(=O)O.O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O

nearest known ligand 0.89

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.89
MAPT P10636 3/20 0.89
MEN1 O00255 2/20 0.89
NPC1 O15118 2/20 0.89
HTT P42858 2/20 0.89
RAB9A P51151 2/20 0.89
KMT2A Q03164 2/20 0.89
SMN1; SMN2 Q16637 2/20 0.89
ALDH1A1 P00352 2/20 0.89
PKM P14618 2/20 0.89
MAPK1 P28482 2/20 0.89
BLM P54132 2/20 0.89
TDP1 Q9NUW8 2/20 0.89
AURKA O14965 1/20 0.89
PDPK1 O15530 1/20 0.89
JAK2 O60674 1/20 0.89
GMNN O75496 1/20 0.89
EGFR P00533 1/20 0.89
TP53 P04637 1/20 0.89
CYP1A2 P05177 1/20 0.89

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Niclosamide SCHEMBL29363878 0.94 KMT2A (1.00) LMNAMAPTMEN1NPC1HTT
Niclosamide SCHEMBL28313524 0.94 KMT2A (1.00) LMNAMAPTMEN1NPC1HTT
Niclosamide SCHEMBL6662409 0.94 KMT2A (1.00) LMNAMAPTMEN1NPC1HTT
Niclosamide SCHEMBL67182 0.94 KMT2A (1.00) LMNAMAPTMEN1NPC1HTT
Niclosamide SCHEMBL27365268 0.94 KMT2A (1.00) LMNAMAPTMEN1NPC1HTT
Niclosamide SCHEMBL31098821 0.93 KMT2A (0.97) LMNAMAPTMEN1NPC1HTT
Niclosamide SCHEMBL2061202 0.93 KMT2A (0.97) LMNAMAPTMEN1NPC1HTT
Niclosamide SCHEMBL27937315 0.93 KMT2A (0.97) LMNAMAPTMEN1NPC1HTT
Niclosamide SCHEMBL16686086 0.92 KMT2A (0.95) LMNAMAPTMEN1NPC1HTT
Niclosamide SCHEMBL1526777 0.92 KMT2A (0.95) LMNAMAPTMEN1NPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113382736-A Compounds, compositions and methods for treating androgen mediated diseases 加利福尼亚大学董事会 2021-09-10 CN disclosed
EP-3873479-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF ANDROGEN-MEDIATED DISEASE The Regents of the University of California (US) 2021-09-08 EP disclosed
US-20210253628-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF ANDROGEN-MEDIATED DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253628-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF ANDROGEN-MEDIATED DISEASE SRD5A1, STS, CYP17A1 LMNA 3992/4885MAPT 2734/4885MEN1 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.